Header Logo

Connection

Cynthia Comella to Male

Back to Details
This is a "connection" page, showing publications Cynthia Comella has written about Male.
Cynthia Comella
Connection Strength
1.179
Male
  1. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2021 Mar; 268(3):903-912.
    View in: PubMed
    Score: 0.057
  2. Reliability, feasibility and satisfaction of telemedicine evaluations for cervical dystonia. J Telemed Telecare. 2020 Oct; 26(9):560-567.
    View in: PubMed
    Score: 0.052
  3. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat Disord. 2018 07; 52:94-97.
    View in: PubMed
    Score: 0.048
  4. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. J Neurol Sci. 2017 May 15; 376:84-90.
    View in: PubMed
    Score: 0.045
  5. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.042
  6. When brawn benefits brain: physical activity and Parkinson's disease risk. Brain. 2015 Feb; 138(Pt 2):238-9.
    View in: PubMed
    Score: 0.039
  7. An international survey of patients with cervical dystonia. J Neurol. 2015; 262(4):837-48.
    View in: PubMed
    Score: 0.039
  8. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014 Apr; 20(4):405-8.
    View in: PubMed
    Score: 0.036
  9. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(?)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707.
    View in: PubMed
    Score: 0.034
  10. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug; 28(9):1230-40.
    View in: PubMed
    Score: 0.034
  11. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.030
  12. Can families be screened for cervical dystonia using a telephone interview? Nat Clin Pract Neurol. 2006 Jan; 2(1):20-1.
    View in: PubMed
    Score: 0.021
  13. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 08; 65(9):1423-9.
    View in: PubMed
    Score: 0.020
  14. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005 Apr 26; 64(8):1450-1.
    View in: PubMed
    Score: 0.020
  15. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003 Mar; 18(3):303-312.
    View in: PubMed
    Score: 0.017
  16. Determinants of gait dystonia severity in cerebral palsy. Dev Med Child Neurol. 2023 07; 65(7):968-977.
    View in: PubMed
    Score: 0.017
  17. Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
    View in: PubMed
    Score: 0.015
  18. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.014
  19. KICK OUT PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson's Disease. PLoS One. 2020; 15(9):e0237777.
    View in: PubMed
    Score: 0.014
  20. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.014
  21. Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord. 2020 03; 35(3):450-456.
    View in: PubMed
    Score: 0.013
  22. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.013
  23. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.013
  24. Sensory Tricks Are Associated with Higher Sleep-Related Quality of Life in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2019; 9.
    View in: PubMed
    Score: 0.013
  25. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.013
  26. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.012
  27. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998 Aug; 51(2):526-9.
    View in: PubMed
    Score: 0.012
  28. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord. 1998 May; 13(3):552-5.
    View in: PubMed
    Score: 0.012
  29. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.012
  30. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018 02 01; 75(2):219-226.
    View in: PubMed
    Score: 0.012
  31. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350.
    View in: PubMed
    Score: 0.012
  32. Factors Associated With Ambulatory Activity in De Novo Parkinson Disease. J Neurol Phys Ther. 2017 Apr; 41(2):93-100.
    View in: PubMed
    Score: 0.011
  33. Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial. J Neurophysiol. 2016 11 01; 116(5):2298-2311.
    View in: PubMed
    Score: 0.011
  34. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.010
  35. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63.
    View in: PubMed
    Score: 0.010
  36. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.010
  37. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp. 2015 Mar; 36(3):1165-79.
    View in: PubMed
    Score: 0.010
  38. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord. 2015 Feb; 30(2):278-83.
    View in: PubMed
    Score: 0.010
  39. Akathisia in Parkinson's disease. Mov Disord. 1994 Sep; 9(5):545-9.
    View in: PubMed
    Score: 0.009
  40. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.009
  41. Subthalamic nucleus--sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease. Neurobiol Aging. 2015 Jan; 36(1):462-9.
    View in: PubMed
    Score: 0.009
  42. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22.
    View in: PubMed
    Score: 0.009
  43. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.009
  44. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8.
    View in: PubMed
    Score: 0.009
  45. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2014 Jan; 71(1):62-7.
    View in: PubMed
    Score: 0.009
  46. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013 Aug; 12(8):747-55.
    View in: PubMed
    Score: 0.009
  47. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.009
  48. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.008
  49. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease. JAMA Neurol. 2013 Jan; 70(1):100-6.
    View in: PubMed
    Score: 0.008
  50. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.008
  51. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology. 1992 Jul; 42(7):1307-10.
    View in: PubMed
    Score: 0.008
  52. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.008
  53. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992 Apr; 42(4):878-82.
    View in: PubMed
    Score: 0.008
  54. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 01; 78(18):1434-40.
    View in: PubMed
    Score: 0.008
  55. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011 Dec; 17(10):740-4.
    View in: PubMed
    Score: 0.008
  56. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.008
  57. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.007
  58. Jaw-opening dystonia: Quality of life after botulinum toxin injections. Ear Nose Throat J. 2011 Feb; 90(2):E9.
    View in: PubMed
    Score: 0.007
  59. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology. 2011 Jan 25; 76(4):319-26.
    View in: PubMed
    Score: 0.007
  60. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100.
    View in: PubMed
    Score: 0.007
  61. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. Mov Disord. 2010 Oct 15; 25(13):2035-43.
    View in: PubMed
    Score: 0.007
  62. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22.
    View in: PubMed
    Score: 0.007
  63. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010 Aug 15; 25(11):1627-32.
    View in: PubMed
    Score: 0.007
  64. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010 Aug 15; 25(11):1708-14.
    View in: PubMed
    Score: 0.007
  65. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8.
    View in: PubMed
    Score: 0.007
  66. Basal ganglia hypoactivity during grip force in drug na?ve Parkinson's disease. Hum Brain Mapp. 2010 Dec; 31(12):1928-41.
    View in: PubMed
    Score: 0.007
  67. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22.
    View in: PubMed
    Score: 0.007
  68. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. J Neurosurg. 2009 Feb; 110(2):229-33.
    View in: PubMed
    Score: 0.006
  69. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009 Apr 21; 72(16):1378-84.
    View in: PubMed
    Score: 0.006
  70. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease? Clin Neurophysiol. 2009 Feb; 120(2):390-7.
    View in: PubMed
    Score: 0.006
  71. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5.
    View in: PubMed
    Score: 0.006
  72. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.006
  73. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia. J Mot Behav. 2008 Jul; 40(4):301-13.
    View in: PubMed
    Score: 0.006
  74. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14(5):407-14.
    View in: PubMed
    Score: 0.006
  75. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.006
  76. Association of daytime napping and Parkinsonian signs in Alzheimer's disease. Sleep Med. 2006 Dec; 7(8):614-8.
    View in: PubMed
    Score: 0.005
  77. Rate of force production and relaxation is impaired in patients with focal hand dystonia. Parkinsonism Relat Disord. 2006 Sep; 12(6):363-71.
    View in: PubMed
    Score: 0.005
  78. Strength deficits in primary focal hand dystonia. Mov Disord. 2006 Jan; 21(1):18-27.
    View in: PubMed
    Score: 0.005
  79. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.005
  80. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.005
  81. Force control and disease severity in Parkinson's disease. Mov Disord. 2005 Apr; 20(4):441-450.
    View in: PubMed
    Score: 0.005
  82. Muscle activation patterns in point-to-point and reversal movements in healthy, older subjects and in subjects with Parkinson's disease. Exp Brain Res. 2004 Jul; 157(1):67-78.
    View in: PubMed
    Score: 0.005
  83. Greater impairment of extension movements as compared to flexion movements in Parkinson's disease. Exp Brain Res. 2004 May; 156(2):240-54.
    View in: PubMed
    Score: 0.004
  84. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.004
  85. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003 Jan 14; 60(1):69-73.
    View in: PubMed
    Score: 0.004
  86. Effect of medication on EMG patterns in individuals with Parkinson's disease. Mov Disord. 2002 Sep; 17(5):950-60.
    View in: PubMed
    Score: 0.004
  87. Control of movement distance in Parkinson's disease. Mov Disord. 2001 Nov; 16(6):1048-65.
    View in: PubMed
    Score: 0.004
  88. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
    View in: PubMed
    Score: 0.004
  89. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62.
    View in: PubMed
    Score: 0.004
  90. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8.
    View in: PubMed
    Score: 0.003
  91. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46.
    View in: PubMed
    Score: 0.003
  92. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6.
    View in: PubMed
    Score: 0.003
  93. Sustained effect of high-dose intrathecal baclofen in primary generalized dystonia: a 2-year follow-up study. Mov Disord. 1997 Nov; 12(6):1100-2.
    View in: PubMed
    Score: 0.003
  94. Partial deficiency of antidiuretic hormone in a cat. J Am Vet Med Assoc. 1977 Mar 01; 170(5):545-7.
    View in: PubMed
    Score: 0.003
  95. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10.
    View in: PubMed
    Score: 0.002
  96. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.